Client News

Nyxoah Raises $27 Million through its At-the-Market Offering

Pentixapharm Holding AG Completes IPO in the Prime Standard of the Frankfurt Stock Exchange

CARBIOS Announces Half-Year 2024 Financial results and Presents its Industrial and Commercial Progress

Pentixapharm Holding AG: Placement Price Set at EUR 5.10 per Share, All 3.9 Million Offer Shares Placed

Mainz Biomed Publishes CEO Statement; CEO Guido Baechler Eyes Major Growth and U.S. FDA Trials in 2025

Formycon and Fresenius Kabi Receive FDA Approval for FYB202/ OtulfiTM (ustekinumab-aauz)

DREAM Pivotal Study Data Presented at the International Surgical Sleep Society 2024 Educational Update

FDA Grants Approval for Stelara®1 Biosimilar FYB202/OtulfiTM2 (ustekinumab-aauz)

Formycon and Fresenius Kabi Receive European Commission Approval for FYB202/Otulfi® (ustekinumab) for the Treatment of Serious Inflammatory Diseases

Affluent Medical – H1 2024 RESULTS: Major Advances in All Three Programs, Several Strategic Agreements Signed, Extension of Financial Runway to July 2025